Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-aminooxyethyl-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl]-methyl-sulfonium is a synthetic small molecule nucleoside analog with the chemical formula C13H21N6O4S and a molecular weight of approximately 357.41 g/mol. The compound features a purine base (adenine) attached to a modified ribose ring and an aminooxyethyl-methylsulfonium group. It is classified as an experimental compound and has not been approved for clinical use or assigned any brand names. Its structure suggests potential activity as a nucleoside analog that could influence nucleic acid metabolism or interact with enzymes involved in DNA/RNA synthesis or repair; however, no specific mechanism of action or therapeutic indication has been established in the literature[1][5]. There are no known developers or manufacturers actively pursuing this molecule for pharmaceutical development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-aminooxyethyl-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl]-methyl-sulfonium.